Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development strategy in the rigorous and cutting-edge field of novel drug therapeutics at ...
Korea Joongang Daily on MSN10h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
USA News Group: Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research ...
Novartis AG (NVS) JPMorgan 43rd Annual Healthcare Conference (Transcript)
Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...
Le Lézard2h
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI ...
FierceBiotech13h
JPM25: GSK’s CSO shares science strategy behind deal-heavy year
And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...